Sensei Biotherapeutics (SNSE) AI Stock Analysis

• Market Cap: $15.11M
• Dividend Yield: N/A
• Average Volume (3M): 38.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: N/A
• EPS Growth: 9.63%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.62
• Shares Outstanding: 1,261,290
• 10 Day Avg. Volume: 109,584
• 30 Day Avg. Volume: 38,927
• PEG Ratio: 4.98
• Price to Book (P/B): 6.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.92
• Enterprise Value/Market Cap: -1.01
• Enterprise Value/Revenue: 3.14
• Enterprise Value/Gross Profit: 74.03
• Enterprise Value/Ebitda: 0.64
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $12.00 ▲(5.08% Upside)

The score is held back primarily by weak financial performance (no meaningful revenue, ongoing losses, and cash burn) and limited valuation support due to negative earnings. Offsetting factors include strong technical momentum (price above major moving averages with positive MACD) and mixed corporate developments, where strategic review and program discontinuation temper earlier trial-positive news.

Positive Factors

Clinical Efficacy Signal

A robust 6-month PFS (50% at 15 mg/kg) in PD-(L)1 resistant patients is a durable clinical signal for a hard-to-treat population. Such differentiated efficacy and tolerability can underpin licensing, partnerships, or asset sale value even if the company lacks resources to commercialize directly.

Conservative Leverage

Very low leverage reduces bankruptcy and refinancing risk for a clinical-stage biotech. This conservative capital structure preserves optionality during a strategic review, making it easier to pursue licensing, collaborations, or orderly asset transactions without heavy debt constraints.

Management Retention Actions

Formal retention agreements and enhanced compensation align senior management with an orderly strategic review. Leadership continuity limits execution risk, aiding negotiations for partnerships, asset sales, or restructuring and improving the odds of extracting value from clinical assets.

Negative Factors

Cash Burn

Sustained negative operating and free cash flow of roughly -$22M TTM creates an urgent need for financing or asset monetization. Over the coming months this structural cash burn constrains the company’s ability to fund trials or pursue development milestones without dilutive raises or strategic transactions.

Program Discontinuation & Strategic Review

Shelving the lead program and launching a strategic review is a structural negative: it removes the primary near-term clinical and commercial value driver. This heightens execution uncertainty and increases the probability of asset sale, licensing, or wind-down outcomes rather than product commercialization.

No Revenue & Equity Erosion

The company has generated no meaningful commercial revenue while incurring sizable recurring losses, and historical equity has declined materially. This structural lack of revenue and capital erosion limits self-funding capability and increases reliance on external financing or disposals to sustain operations.

Sensei Biotherapeutics Business Overview & Revenue Model

Company Description

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

How the Company Makes Money

Sensei Biotherapeutics makes money primarily through the development and potential commercialization of its proprietary immunotherapy products. The company's revenue model is centered around advancing its product candidates through clinical trials, with the ultimate goal of gaining regulatory approval for commercialization. Key revenue streams may include licensing agreements, collaborations, and partnerships with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on future sales of their developed therapies. Additionally, Sensei may secure funding through grants and research collaborations that support its R&D efforts. However, as a clinical-stage company, Sensei is primarily focused on research and development activities and may not yet have significant product sales revenue.

Sensei Biotherapeutics Financial Statement Overview

Summary

Sensei Biotherapeutics faces significant financial challenges, primarily due to a lack of revenue and ongoing net losses. While there are some improvements in the balance sheet, such as reduced debt levels, the overall financial health is weak with negative cash flows and profitability metrics. The company needs to focus on revenue generation and operational efficiency to improve its financial standing.

Income Statement

Sensei Biotherapeutics has not generated any revenue over the past years, which is a significant concern. The company has consistently reported net losses, indicating ongoing challenges in achieving profitability. The EBIT and EBITDA margins are negative, reflecting operational inefficiencies and high operational costs relative to nonexistent revenue.

Balance Sheet

The company's balance sheet shows a moderate level of debt with a debt-to-equity ratio that has improved over time due to a reduction in liabilities and an increase in equity. However, the negative net income impacts the return on equity, and the equity ratio is under pressure due to declining total assets. The improvement in net debt indicates better cash management, but the overall equity position remains weak.

Cash Flow

Operating cash flow is negative, indicating that the company is not generating sufficient cash from its core operations. Free cash flow is consistently negative, which could pose liquidity challenges. The company has been reliant on financing activities to sustain operations, which is not sustainable in the long term without revenue generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-4.85M	0.00	0.00	0.00	0.00	0.00
Gross Profit	-206.00K	-551.00K	-571.00K	-1.81M	-685.00K	-209.00K
EBITDA	-23.85M	-29.52M	-33.39M	-46.56M	-35.44M	-18.20M
Net Income	-24.14M	-30.16M	-34.10M	-48.59M	-36.79M	-20.10M
Balance Sheet
Total Assets	27.59M	45.36M	74.37M	118.38M	153.22M	21.43M
Cash, Cash Equivalents and Short-Term Investments	25.04M	41.34M	65.76M	107.12M	147.62M	16.60M
Total Debt	2.02M	3.85M	6.21M	8.03M	2.35M	685.00K
Total Liabilities	4.58M	6.97M	9.48M	14.97M	6.71M	5.54M
Stockholders Equity	23.01M	38.39M	64.89M	103.41M	146.51M	15.89M
Cash Flow
Free Cash Flow	-22.40M	-24.82M	-32.20M	-39.35M	-32.28M	-18.91M
Operating Cash Flow	-22.38M	-24.67M	-32.02M	-39.03M	-30.26M	-17.70M
Investing Cash Flow	14.54M	22.44M	38.41M	49.95M	-143.12M	-1.40M
Financing Cash Flow	-728.00K	-787.00K	-11.17M	-287.00K	163.94M	35.45M

Sensei Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.42
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNSE, the sentiment is Positive. The current price of 11.42 is above the 20-day moving average (MA) of 10.14, above the 50-day MA of 9.35, and above the 200-day MA of 8.53, indicating a bullish trend. The MACD of 0.74 indicates Negative momentum. The RSI at 61.62 is Neutral, neither overbought nor oversold. The STOCH value of 94.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNSE.

Sensei Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATHA	55 Neutral	$25.95M	-0.66	-89.42%	―	―	66.10%
CLRB	53 Neutral	$15.88M	-0.34	-145.42%	―	―	79.31%
SNSE	52 Neutral	$15.11M	-0.54	-67.47%	―	―	9.63%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BOLT	48 Neutral	$12.38M	-0.31	-81.97%	―	-46.88%	34.83%
COCP	45 Neutral	$15.99M	-1.19	-94.94%	―	―	49.10%
BRTX	44 Neutral	$10.47M	-0.73	-207.73%	―	1.70%	-111.67%

Sensei Biotherapeutics Corporate Events

Sensei Biotherapeutics Updates Executive Retention and Compensation Agreements

On December 22, 2025, Sensei Biotherapeutics, Inc. entered into amended retention agreements with President and Principal Executive Officer Christopher Gerry and Senior Vice President of Finance and Principal Finance and Accounting Officer Josiah Craver, revising key compensatory terms in their employment arrangements. Effective November 14, 2025, the company set Gerry’s annual base salary at $425,000 and Craver’s at $400,000 and made both executives eligible for an annual target bonus equal to 40% of base salary beginning with the 2026 fiscal year; it also established a structure of retention bonuses tied to continued employment into early 2026 or to certain termination scenarios, with enhanced benefits if they are terminated without cause or resign for good reason outside the context of a change in control, contingent on signing a separation and release agreement. The changes strengthen management’s financial incentives to remain with the company during a critical period, potentially providing greater leadership stability and signaling a focus on executive retention to investors and other stakeholders.

The most recent analyst rating on (SNSE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Sensei Biotherapeutics stock, see the SNSE Stock Forecast page.

Sensei Biotherapeutics Discontinues Solnerstotug Development

On October 30, 2025, Sensei Biotherapeutics announced its decision to discontinue the development of solnerstotug and initiate a strategic review to maximize shareholder value. The review may involve asset sales, licensing, collaborations, or a company sale, and includes workforce reductions to preserve cash, while maintaining a small team for compliance and management of ongoing activities.

The most recent analyst rating on (SNSE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Sensei Biotherapeutics stock, see the SNSE Stock Forecast page.

Sensei Biotherapeutics Reports Promising Trial Results

On October 17, 2025, Sensei Biotherapeutics announced promising results from their Phase 1/2 trial of solnerstotug, a monoclonal antibody targeting VISTA, presented at the ESMO Congress 2025. The trial showed a 6-month progression-free survival rate of 50% in the 15 mg/kg dose cohort for PD-(L)1 resistant tumors, surpassing historical benchmarks. The treatment demonstrated a favorable safety profile, with only mild cytokine release syndrome observed. These results support the advancement to Phase 2 studies, which are planned for 2026, focusing on Non-Small Cell Lung Cancer and Merkel Cell Carcinoma, potentially leading to accelerated approval for PD-1 resistant populations.

The most recent analyst rating on (SNSE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Sensei Biotherapeutics stock, see the SNSE Stock Forecast page.